This document discusses the regulatory and manufacturing challenges of cell therapy products. It notes that cell therapies must be aseptically processed but cannot be fully sterilized like traditional drugs. The challenges include controlling differentiation of stem cells into the desired target cell type, developing potency assays, and dealing with variability in biological materials. Manufacturing challenges include developing aseptic processing methods, handling adventitious agents, and scaling up production capacity for either autologous or allogeneic use. Larger centralized facilities face quality oversight and logistical issues, while smaller regional facilities could better concentrate expertise, quality, and handling of incoming/outgoing cells and products.